Shares of Aerie Pharmaceuticals (AERI) are up 75% in after-hours trade after the company announced positive phase 3 results for its Rhopressa trial. The drug Rhopressa is a once daily, triple action eye drop that relieves intraocular pressure in patients
September 16, 2015